EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access

Pharmacokinetics and safety of EVER206, a novel polymyxin antimicrobial, in healthy Chinese subjects

Size Li iD, Xu Zhu, Guoying Cao, Jufang Shen, Xu Zhu, Jicheng Yu, Xiaojie Wu iD, Jufang Wu, Haijing Yang, Nanyang Li, Yingying Hu, Jingjing Wang und 2 weitere

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.01563-23 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Size Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Polymyxins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

EVER206 (also known as SPR206) is a novel polymyxin analog that has shown in vitro potency and in vivo efficacy against multidrug-resistant (MDR) Gram-negative pathogens. This randomized, double-blinded, placebo-controlled, Phase I study evaluated the safety, tolerability, and pharmacokinetics of EVER206 in healthy Chinese subjects. After single administration of 50–300 mg EVER206, the C max ranged from 3.94 to 25.82 mg/L, and the AUC 0-inf ranged from 12.42 to 101.67 h·mg/L. The plasma exposure displayed a linear relationship with the dose administered. After administration of 75 and 100 mg of EVER206 every 8 hours (q8 hour), a steady state was achieved on Day 2. The accumulation ratios of C max and AUC from Day 1 to Day 7 were in the range of 1.12 to 1.3. The elimination half-lives ranged from 2.86 to 4.32 hours in the single-ascending-dose (SAD) study and 4.71 to 6.18 hours in the multiple-ascending-dose (MAD) study. The urinary excretion of unchanged EVER206 increased with the dose, with the mean cumulative fraction ranging from 23.70% to 47.10%. EVER206 was safe and well-tolerated in Chinese healthy subjects. No severe treatment emerging adverse events (TEAEs), serious adverse events, or TEAEs leading to discontinuation were reported. The results of the present study demonstrated a similar safety profile of EVER206 with data reported in an earlier study on SPR206-101. The exposure of EVER206 in Chinese healthy subjects was higher than that in Australian healthy subjects. These results could enable further clinical development of EVER206 in Chinese patients with severe MDR Gram-negative pathogen infections. CLINICAL TRIALS This study was registered at the Chinese Clinical Trial Registry under identifier ChiCTR2200056692 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsPolymyxinsAdultFemaleHumansMaleYoung AdultArea Under CurveChinaDouble-Blind MethodHalf-LifeHealthy VolunteersEast Asian People

Stichwörter der Autor:innen

EVER206SPR206pharmacokineticspolymyxinssafety

Substanzen

Anti-Bacterial AgentsPolymyxins

Autor:innen und Institutionen

  • Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
  • Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai, China.
  • Key Laboratory of Antibiotic Clinical Pharmacology of the National Health Commission, Shanghai, China.
  • National Clinical Research Center for Aging and Medicine, Huashan Hospital, Shanghai, China.
  • Research Ward of Huashan Hospital, Fudan University, Shanghai, China.
  • EVEREST MEDICINES, Shanghai, China.

ORCID-Profile: Size Li, Xiaojie Wu, Haihui Huang, Jing Zhang

Zitieren

APA

Li, S., Zhu, X., Cao, G., Shen, J., Zhu, X., Yu, J., Wu, X., Wu, J., Yang, H., Li, N., Hu, Y., Wang, J., Huang, H., & Zhang, J. (2024). Pharmacokinetics and safety of EVER206, a novel polymyxin antimicrobial, in healthy Chinese subjects. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01563-23

Vancouver

Li S, Zhu X, Cao G, Shen J, Zhu X, Yu J, et al. Pharmacokinetics and safety of EVER206, a novel polymyxin antimicrobial, in healthy Chinese subjects. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01563-23

BibTeX
@article{Li2024,
  author = {Li, Size and Zhu, Xu and Cao, Guoying and Shen, Jufang and Zhu, Xu and Yu, Jicheng and Wu, Xiaojie and Wu, Jufang and Yang, Haijing and Li, Nanyang and Hu, Yingying and Wang, Jingjing and Huang, Haihui and Zhang, Jing},
  title = {Pharmacokinetics and safety of EVER206, a novel polymyxin antimicrobial, in healthy Chinese subjects},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.01563-23}
}
Kostenlos starten →